welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
A Prospective Multicenter Phase II Study of Sunitinib in Patients With Advanced Aggressive Fibromatosis
source: Investigational new drugs
year: 2014
authors: Jo J C, Hong Y S, Kim K P, Lee J L, Lee J, Park Y S, Kim S Y, Ryu J S, Lee J S, Kim T W
summary/abstract:Several studies have reported that imatinib may induce tumor responses and prolonged disease stabilization in aggressive fibromatosis (AF). This effect may relate to the PDGFR-β pathway and KIT mutations. Sunitinib not only inhibits PDGFRs, KIT, and FLT3, it also blocks VEGFRs and thus serves as an antiangiogenic agent. The aim of this prospective multicenter uncontrolled study was to evaluate the efficacy and safety of sunitinib in patients with advanced AF. Nineteen patients with pathologically proven AF were recruited between June, 2008, and March, 2012, from three centers. One treatment cycle consisted of 37.5 mg/day sunitinib for 4 weeks without a break. The primary endpoint was tumor response rate according to RECIST 1.0. Ten (53 %) patients were female and the median age was 30 years (range, 22-67). Most of the primary sites were intra-abdominal (12, 63.2 %), and AF associated with familial adenomatous polyposis in ten patients (52.6 %). With a median of six cycles per patients (range, 1-47 cycles), five patients (26.3 %) achieved a partial response and eight (42.1 %) had stable disease. The overall response rate was 26.3 % (95 % confidence interval [CI], 6.3-45.7) in intention-to-treat analysis. With a median follow-up time of 20.3 months (range, 1.8-50.7), the 2-year rates of progression-free and overall survival were 74.7 % and 94.4 %, respectively. Grade 3 or 4 adverse events of sunitinib that occurred in >5 % of patients were neutropenia (33.3 %), diarrhea (5.3 %), and hand-foot syndrome (5.3 %). In 3 of 12 patients with mesenteric AF, mesenteric mass bleeding (n = 1), bowel perforation (n = 1), and bowel fistula (n = 1) with tumor mass necrosis were observed early during sunitinib treatment. Therefore, sunitinib showed potential antitumor activity and may be useful for the management of non-mesenteric AF.
organization: University of Ulsan College of MedicineDOI: 10.1007/s10637-013-0059-0
read more full text source
expertly curated content related to this topic
-
A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis PatientsThe purpose of this study is to determin...
-
A Randomized, Double-Blind, Placebo-Controlled Trial of the Effects of Rofecoxib, a Selective Cyclooxygenase-2 Inhib...PURPOSE : The aim of this study was to e...
-
A Pilot Open-Label Crossover Bioavailability Study of Celecoxib in Healthy VolunteersA pharmacokinetic study in healthy volun...
-
18F-FES PET/CT in Imaging Patients With Desmoid TumorsThis pilot clinical trial studies fluori...
-
Cancer Prevention Pharmaceuticals in Collaboration with the NCI and Vanderbilt University Medical Center Initiates P...Cancer Prevention Pharmaceuticals, Inc. ...
-
Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous PolyposisColorectal cancer (CRC) is a leading cau...
-
Independent Data Monitoring Committee Recommends Continuation of Cancer Prevention Pharmaceuticals’ Phase 3 Trial ...Cancer Prevention Pharmaceuticals, Inc. ...